Exelixis Inc (EXEL)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH

1851 HARBOR BAY PARKWAY ALAMEDA, CA 94502

Uses comparative genomics and model system genetics to identify novel genes or proteins that represent potential product targets or drugs to treat disease or prevent disease initiation or progression. The company's most advanced pharmaceutical program focuses on small molecules in cancer.

Data as of 2020-08-09
Market Cap6.909 Billion Shares Outstanding308.996 Million Avg 30-day Volume2.193 Million
P/E Ratio25.1 Dividend Yield EPS0.89
Price/Sales6.92 Price cash flow ratio18.1 Price free cash flow ratio18.6
Book Value5.93 Price to Tangible Book3.9 Alpha0.02
Short Interest Ratio % Short Interest to Float R-squared0.133866
BETA1.47296 52-week High/Low27.8 / 13.67 Stddev0.16929
View SEC Filings from EXEL instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 4 1 (0.07%)
13F Filers holding this stock: 322 67 (4.39%)
Aggregate 13F shares on 03/31/2020: 244.018 Million 101.736 Million
Aggregate 13F shares on 12/31/2019: 239.916 Million 101.507 Million
Percent change: 1.71% 0.23%
Funds creating new positions: 50 11
Funds Adding to an existing position: 116 29
Funds closing out their position: 41 16
Funds reducing their position: 98 23
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding EXEL (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding EXEL BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

3.2 Thousand total shares from 1 transactions

Exercise Derivative Conversion (M)

300 Thousand total shares from 3 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SCANGOS GEORGE A

  • Director
28,112 2020-08-03 12

GARLAND J. SCOTT

  • Director
0 2020-07-31 0

MORRISSEY MICHAEL PRESIDENT AND CEO

  • Officer
  • Director
1,135,348 2020-07-20 23

HALEY PATRICK J. EVP, COMMERCIAL

  • Officer
146,376 2020-07-20 12

WYSZOMIERSKI JACK L

  • Director
0 2020-06-18 2

PAPADOPOULOS STELIOS

  • Director
0 2020-06-17 3

LAMB PETER EVP, SCIENTIFIC STRATEGY & CSO

  • Officer
143,636 2020-06-08 6

SENNER CHRISTOPHER J.

  • Director
0 2020-06-08 4

SCHWAB GISELA PRES, PROD DEV & MED AFF & CMO

  • Officer
340,843 2020-06-04 12

SMITH JULIE

  • Director
0 2020-06-03 1

GARBER ALAN M

  • Director
5,890 2020-06-01 3

WILLSEY LANCE

  • Director
0 2020-05-21 3

COHEN CHARLES

  • Director
0 2020-05-21 2

FELDBAUM CARL B

  • Director
0 2020-05-21 3

MARCHESI VINCENT T

  • Director
90,212 2020-05-21 3

POSTE GEORGE

  • Director
128,330 2020-05-21 3

FREIRE MARIA C

  • Director
40,102 2020-05-21 1

MCCORMICK FRANK CHAIRMAN OF ONCOLOGY

  • Officer
1,300,568 2020-05-19 0

HESSEKIEL JEFFREY EVP AND GENERAL COUNSEL

  • Officer
251,312 2020-05-13 6

KARBE FRANK

  • Director
0 2020-05-05 0

HELLER FRANCES K

  • Director
47,961 2017-10-13 0

BURKE DEBORAH SVP & CHIEF FINANCIAL OFFICER

  • Officer
19,990 2014-11-15 0

SIMONTON PAMELA A EVP, EXELIXIS

  • Officer
28,091 2014-02-15 0

RIVERA LUPE M EVP, OPERATIONS

  • Officer
22,051 2011-08-15 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

MORRISSEY MICHAEL - Director - Officer PRESIDENT AND CEO by trust

2020-07-22 G 35,863 a 1,031,635 1,135,348.00 indirect

MORRISSEY MICHAEL - Director - Officer PRESIDENT AND CEO

2020-07-22 G 35,863 d 85,985 1,135,348.00 direct

MORRISSEY MICHAEL - Director - Officer PRESIDENT AND CEO

2020-07-20 M 100,000 d 0 1,135,348.00 direct

MORRISSEY MICHAEL - Director - Officer PRESIDENT AND CEO

2020-07-20 F 64,137 $25.60 d 121,848 1,135,348.00 direct

MORRISSEY MICHAEL - Director - Officer PRESIDENT AND CEO

2020-07-20 M 100,000 $6.21 a 185,985 1,135,348.00 direct

HALEY PATRICK J. - Officer EVP, COMMERCIAL

2020-07-20 S 3,151 $25.36 d 112,189 146,376.00 direct yes

MORRISSEY MICHAEL - Director - Officer PRESIDENT AND CEO

2020-07-14 G 35,559 d 85,985 1,135,348.00 direct

MORRISSEY MICHAEL - Director - Officer PRESIDENT AND CEO by trust

2020-07-14 G 35,559 a 995,772 1,135,348.00 indirect

MORRISSEY MICHAEL - Director - Officer PRESIDENT AND CEO

2020-07-10 M 100,000 $6.21 a 185,985 1,099,485.00 direct

MORRISSEY MICHAEL - Director - Officer PRESIDENT AND CEO

2020-07-10 M 100,000 d 100,000 1,099,485.00 direct

MORRISSEY MICHAEL - Director - Officer PRESIDENT AND CEO

2020-07-10 F 64,441 $24.94 d 121,544 1,099,485.00 direct

MORRISSEY MICHAEL - Director - Officer PRESIDENT AND CEO by trust

2020-06-24 G 35,189 a 960,213 1,099,485.00 indirect

MORRISSEY MICHAEL - Director - Officer PRESIDENT AND CEO

2020-06-24 G 35,189 d 85,985 1,099,485.00 direct

MORRISSEY MICHAEL - Director - Officer PRESIDENT AND CEO

2020-06-19 M 100,000 $6.21 a 185,985 1,063,926.00 direct

MORRISSEY MICHAEL - Director - Officer PRESIDENT AND CEO

2020-06-19 M 100,000 d 200,000 1,063,926.00 direct

MORRISSEY MICHAEL - Director - Officer PRESIDENT AND CEO

2020-06-19 F 64,811 $24.18 d 121,174 1,063,926.00 direct
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments